Multidisciplinary lung cancer clinics might help patients and the system save on treatment costs while improving patient experiences, according to an abstract presented at CHEST 2020.
Spending less on health care is beneficial to both patients and the health care system, but it can be difficult in oncology, where drugs are expensive and treatment is often complicated, especially when disease is caught in later stages. But one way to save on costs while improving patient experiences might be multidisciplinary clinics (MDC), according to an abstract presented at CHEST 2020.1
Collaborative, multidisciplinary discussions and care have been shown to reduce costs and facilitate better disease management.2,3 The new economic evaluation assessed a clinic at Kingston Health Sciences Centre (KHSC) in Kingston, Ontario, Canada, where a previous study found that newly diagnosed lung cancer patients received oncology assessments faster, had shorter times to treatment, and made a reduced number of clinic visits in the MDC model with concurrent pulmonology and oncology consultations.4
In the new study, researchers retrospectively assessed resource use and costs when an MDC model was implemented in lung cancer care over a nearly 2-year period. They examined costs from the societal level and presented the findings in 2019 Canadian dollars (CDN).
Patient data from February 2017 to December 2018 informed the analysis of total cost savings due to less clinic visits. Researchers also factored in productivity loss, travel expenses, and the administrative costs related to booking visits. The data included 350 patients seen at the MDC, with 271 (77%) of the participants over 65 years of age.
Over the course of the study, the MDC patients required 1.06 fewer oncology visits between lung cancer diagnosis and treatment initiation, for a total of 371 fewer oncology visits for the patient population overall.
The Government of Canada automobile allowance rate ($0.58/km [$0.44 USD per km]) and mean round trip distance to KHSC from patients’ homes (101.96 km per visit) were used to estimate travel costs, which amounted to about $21,940.94 ($16,535.49 USD) in savings. Parking-related expense savings were about $2,226 ($1,677.59 USD). The total of $24,166.94 ($18,213.08 USD) in savings between 350 patients amounted to roughly $70 ($52.75 USD) per patient.
Patient and caregiver productivity loss was estimated using the average wage for Canadians over 25 years of age ($29.55/hour [$22.27 USD]), and included all patients under 65 years of age (23% of the study population). Researchers factored in travel time (61.2 minutes), clinic visit time (75.6 minutes), parking or time spent locating the clinic (15 minutes), and an average of 1.25 caregivers per patient.
Total patient and caregiver productivity-loss cost savings were estimated at $6,379.40 ($4,807.75 USD) and $17,335.32 ($13,064.53 USD), respectively. Clinic administrative level savings amounted to $508.27 ($383.05 USD), assuming 3 minutes per booking and an average wage of $27.33 ($20.60 USD) per hour.
The study concluded that the lung cancer MDC led to economic benefits for both patients and the health care system, with an estimated total cost reduction of $48,389.93 ($36,468.41 USD) (range: $37,173.37 - $122,896.42 [$28,015.20 - $92.619.20 USD]) over the roughly 2-year period for 350 patients. The benefits were enough to consider the study evidence in favor of MDCs for lung cancer care.
[Editor’s note: All monetary conversions were done using Bank of Canada annual exchange rate data.]
References
1. Johnson A, Katyukha A, Stone C, Parker C, Robinson A, Digby G. Patient and health system cost savings in a multidisciplinary lung cancer clinic. Presented at: CHEST 2020; October 18-21, 2020. Abstract A1334. doi:10.1016/j.chest.2020.08.1212
2. Rosenberg J. Multidisciplinary Collaborative Care Reduces Costs, Improves End-of-Life Care for Patients With IPF. July 25, 2020. Accessed November 18, 2020. https://www.ajmc.com/view/multidisciplinary-collaborative-care-reduces-costs-improves-endoflife-care-for-patients-with-ipf
3. Rosenberg J. Multidisciplinary Discussion Benefits Diagnosis, Management of ILD, Study Finds. September 18, 2020. Accessed November 18, 2020. https://www.ajmc.com/view/multidisciplinary-discussion-benefits-diagnosis-management-of-ild-study-finds
4. Stone C, Robinson A, Brown E, et al. Improving Timeliness of Oncology Assessment and Cancer Treatment Through Implementation of a Multidisciplinary Lung Cancer Clinic. J Oncol Pract. 2019;15(2):e169-e177. doi:10.1200/JOP.18.00214
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Early Intervention, Targeted Strategies Needed to Improve Disparities, Survival in Patients With IPF
October 17th 2024Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).
Read More
CHEST 2024 Posters Reveal Disparities in Acute Coronary Syndrome Care, Outcomes
October 16th 2024Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring the urgent need for targeted interventions to address these inequities.
Read More
Ineligibility, Limitations to PR Uptake in Patients With AECOPD
October 15th 2024Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.
Read More